Harbour Investments Inc. trimmed its position in Abbott Laboratories (NYSE:ABT – Free Report) by 10.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 166,346 shares of the healthcare product maker’s stock after selling 20,028 shares during the period. Harbour Investments Inc.’s holdings in Abbott Laboratories were worth $16,440,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after buying an additional 6,769,518 shares in the last quarter. State Street Corp raised its holdings in shares of Abbott Laboratories by 1.7% in the 2nd quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after acquiring an additional 1,350,766 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Abbott Laboratories in the 2nd quarter valued at about $1,603,607,000. Deutsche Bank AG boosted its position in shares of Abbott Laboratories by 18.6% during the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock valued at $1,515,963,000 after acquiring an additional 2,614,965 shares during the last quarter. Finally, Legal & General Group Plc bought a new stake in shares of Abbott Laboratories during the 2nd quarter valued at about $1,082,524,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on ABT shares. Barclays initiated coverage on Abbott Laboratories in a report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price objective for the company. Argus downgraded shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Wells Fargo & Company lifted their target price on shares of Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday, October 22nd. Wall Street Zen upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, October 24th. Finally, Citigroup cut their price target on shares of Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating for the company in a research note on Thursday, October 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $118.32.
View Our Latest Stock Analysis on Abbott Laboratories
Insiders Place Their Bets
In other Abbott Laboratories news, EVP Mary Moreland sold 3,500 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total value of $406,000.00. Following the completion of the sale, the executive vice president owned 100,791 shares of the company’s stock, valued at $11,691,756. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.46% of the stock is owned by insiders.
Abbott Laboratories Price Performance
ABT stock traded up $1.34 during mid-day trading on Friday, hitting $108.59. 6,199,121 shares of the stock were exchanged, compared to its average volume of 9,559,261. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.45 and a quick ratio of 1.00. The business has a fifty day moving average price of $103.93 and a 200 day moving average price of $101.74. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $132.02. The stock has a market capitalization of $188.08 billion, a price-to-earnings ratio of 40.52, a PEG ratio of 1.88 and a beta of 0.54.
Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.42. The firm had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.30 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.
Abbott Laboratories Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $0.63 dividend. The ex-dividend date is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s payout ratio is presently 94.03%.
Abbott Laboratories Profile
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Featured Stories
- Five stocks we like better than Abbott Laboratories
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
